01—Abstract
Summary
Summary of the 10-K filed February 25, 2021. Cited figures are marked; the original filing is the authoritative source.
Danaher Corporation (DHR) reported strong performance in its 2020 fiscal year, characterized by significant revenue growth driven primarily by the substantial acquisition of Cytiva and robust core sales growth across its segments.
The Life Sciences segment showed particular strength, bolstered by Cytiva's performance and demand related to COVID-19 testing and vaccine development. The company navigated the challenges of the COVID-19 pandemic effectively, demonstrating resilience through its diversified business model and the application of the Danaher Business System (DBS).
While the pandemic did impact certain areas of the business, overall, Danaher managed operational and financial impacts, leveraging cost-saving measures and adapting to changing market dynamics. The company's strong operating profit margins and cash flow generation underscore its operational efficiency and financial health, positioning it well for continued growth and strategic investments in science and technology.
02—Key points
Key Highlights
- Danaher reported a 24.5% increase in total sales for 2020, largely driven by the strategic acquisition of Cytiva in March 2020 for approximately $20.7 billion.
- Core sales (excluding acquisitions/divestitures and currency impact) grew by 6.5%, with core sales including Cytiva showing a 9.5% increase, demonstrating underlying business strength.
- The Life Sciences segment saw significant growth with a 52.0% increase in total sales, primarily due to the Cytiva acquisition and strong demand for bioprocessing instruments and consumables related to COVID-19 vaccine development.
- The Diagnostics segment also performed well, with a 13.0% increase in total sales, driven by molecular diagnostics and acute care instruments and consumables, partly due to COVID-19 related demand.
- Operating profit margin improved to 19.0% in 2020 from 18.3% in 2019, reflecting operational efficiencies and cost management, despite some acquisition-related charges.
- The company generated strong operating cash flow of $6.2 billion in 2020, a 70% increase from 2019, supported by higher earnings and working capital management.
- Danaher maintains a strong liquidity position with $6.0 billion in cash and cash equivalents as of December 31, 2020, and substantial availability under its credit facilities.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2020, Danaher Corp kept $0.16.
- Revenue$22.28B100.0%
- Cost of revenue−$9.81B44.0%
- Gross profit$12.47B56.0%
- Operating costs−$8.24B37.0%
- Operating income$4.23B19.0%
- Interest, other & tax−$585.0M2.6%
- Net income$3.65B16.4%
Where FY2020 revenue went
$22.28B- Cost of revenue: $9.81B, 44% of revenue
- SG&A: $6.90B, 31% of revenue
- Net income: $3.65B, 16% of revenue
- R&D: $1.35B, 6.0% of revenue
- Interest, other & tax: $585.0M, 2.6% of revenue
Kept 16% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2020filed February 25, 2021Financial Statements
FY2020 against FY2019
| Line item | FY2020FY2019 | Change |
|---|---|---|
| Revenue | $22.28B$17.91B | +24.4% |
| Cost of Revenue | $9.81B$7.93B | +23.7% |
| Gross Profit | $12.47B$9.98B | +24.9% |
| R&D Expenses | $1.35B$1.13B | +19.7% |
| SG&A Expenses | $6.90B$5.59B | +23.4% |
| Operating Income | $4.23B$3.27B | +29.4% |
| Interest Expense | $275.00M$108.00M | +154.6% |
| Net Income | $3.65B$3.01B | +21.2% |
| EPS (Basic) | $4.97$4.11 | +20.9% |
| EPS (Diluted) | $4.89$4.05 | +20.7% |
| Shares Outstanding (Basic) | 706.20M715.00M | −1.2% |
| Shares Outstanding (Diluted) | 718.70M725.50M | −0.9% |
05—Questions
Frequently Asked Questions
What was the most significant event for Danaher in 2020?
The most significant event was the acquisition of Cytiva, the Biopharma business of GE's Life Sciences division, for approximately $20.7 billion. This acquisition significantly expanded Danaher's Life Sciences segment, contributing substantially to the company's overall revenue growth in 2020.
How did the COVID-19 pandemic affect Danaher's performance?
The pandemic had a mixed impact. While it led to lower demand in some areas (e.g., certain non-COVID-19 applications, some industrial products), it also drove increased demand for products and services related to COVID-19 testing, diagnostics, and vaccine development and production, particularly in the Life Sciences and Diagnostics segments. The company also implemented cost-saving measures due to reduced business travel and other activities.
What is Danaher's strategy for growth?
Danaher's strategy focuses on three key priorities: strengthening competitive advantage through the Danaher Business System (DBS), enhancing its portfolio in attractive science and technology markets through strategic capital allocation (including acquisitions), and attracting and retaining exceptional talent.
How did Danaher manage its debt in 2020?
Danaher's debt levels increased significantly due to the Cytiva acquisition. The company financed the acquisition through a combination of debt issuances (euro-denominated and U.S. dollar-denominated notes) and equity offerings. As of December 31, 2020, total debt was approximately $21.2 billion. The company also repaid some existing debt and maintained significant availability under its credit facilities.
06—Continue